Note | HtrA3 belongs to the HtrA family of ATP-independent serine proteases, homologues of the HtrA serine protease from the bacterium Escherichia coli. HtrA proteins are very well conserved in evolution. Structurally, they are characterized by the presence of a trypsin-like protease domain with the catalytic triad His-Asp-Ser and at least one PDZ domain at the C-terminal end. General function of the HtrA proteins is the defense against cellular stresses (such as heat shock, oxidative stress) causing aberrations in protein structure. At least, four human HtrA proteins have been identified. They are involved in important physiological processes including maintenance of mitochondrial homeostasis, cell death (apoptosis, necrosis, anoikis) and cell signaling. Disturbances in their functions may contribute to the development of several disorders such as cancer, arthritis and neurodegenerative disorders (reviewed by Chien et al., 2009a; Zurawa-Janicka et al., 2010; Clausen et al., 2011). |
| |
|  |
| |
| Figure 2. Domain organization of human HtrA3 protein. Schematic organization of the long (A) and short (B) isoform of HtrA3 is presented. S: signal peptide, IB: domain with homology to insulin-like growth factor binding proteins, KM: Kazal type serine protease inhibitor motif, PROTEOLYTIC: trypsin-like domain, PDZ: PDZ domain, DWKKRFI/APSLAVH: amino acid residues different in the HtrA3 variants. The insulin-like growth factor binding domain (IB) and Kazal type inhibitor motif (KM) are homologous to Mac25 protein. Amino acid residues of the HtrA3 catalytic triad are marked (numbers indicate the position of the given residue in a polypeptide chain). |
| |
Description | The open reading frame (ORF) of the long splice variant of HTRA3 mRNA encodes a polypeptide of 453 aa, mass of approximately 49 kDa. The long isoform of HtrA3 (HtrA3-L) contains a signal secretory peptide at the N-terminus (1-17), a domain with homology to the insulin-like growth factor binding proteins (29-94 aa) and a Kazal-type inhibitor motif (89-126) followed by a serine protease domain (176-341 aa) with the catalytic triad His191-Asp219-Ser305 and one PDZ domain (384-440 aa) at the C-terminal end. Domain with homology to the insulin-like growth factor binding proteins and a Kazal-type inhibitor motif shares homology with Mac25 protein. The PDZ domain mediates specific protein-protein interactions (Figure 2). The ORF of the short splice variant of HTRA3 mRNA encodes a polypeptide of 357 aa, mass of about 38 kDa. Contrary to HtrA3-L, the short isoform of HtrA3 (HtrA3-S) lacks the PDZ domain. Moreover, the last seven C-terminal residues of HtrA3-S (APSLAVH) are completely different from the corresponding residues in HtrA3-L (DWKKRFI) (Figure 2) (Nie et al., 2003). Under treatment of lung cancer cell lines with chemotherapeutic agents (cisplatin, etoposide) a removal of the N-terminal Mac25 domain has been observed (Beleford et al., 2010b). The proteolytic processing is believed to be an autocatalytic process since the catalytically inactive mutant did not undergo such modification. Substitution of the serine residue belonging to the protease catalytic site with alanine abolished autocatalytic degradation (Singh et al., 2012). Solely the structure of PDZ domain of HtrA3 was determined by the X-ray crystallography (Runyon et al., 2008). The Myosin-9 was identified as a first endogenous binding protein of HtrA3 in the placenta (Singh et al., 2012). |
Expression | Both variants of HTRA3 transcripts are widely expressed in the human body with variable levels in different organs (Nie et al., 2003). Reciprocal ratio of the long HTRA3 mRNA to short HTRA3 mRNA is dependent on the type of tissue. The highest expression of HTRA3 was observed in heart tissues and reproductive organs (ovary, uterus and placenta) (Nie et al., 2003). HTRA3 is expressed predominantly in the glandular epithelium, endometrium and decidual cells during preparation of endometrium for embryo implantation in the early pregnancy. The maximal expression of placental HTRA3 is observed during the first trimester and then it decreases dramatically (Nie et al., 2005; Nie et al., 2006a; Li et al., 2011). Placental HtrA3 expression is negatively regulated through oxygen tension in the placenta (Li et al., 2011). It was clearly demonstrated that expression of HTRA3 is up-regulated during folliculogenesis and luteinisation in the rhesus monkey ovary (Bowden et al., 2008). These data indicate an important role of HTRA3 in placenta development and function. Transcription of HTRA3 gene is stimulated through an indirect mechanism involving the MEK/ERK pathway in clear cell renal carcinoma (Theoleyre et al., 2010). In vitro transcriptional studies revealed that infection of chicken chondrocytes by bacterium Mycoplasma synoviae up-regulates of HTRA3 gene as an apoptosis-like event (Dusanic et al., 2012). Beleford with co-workers showed that expression of HTRA3 is silenced by cigarette smoke-mediated methylation in lung tumors. This epigenetic modification increased the resistance of lung cancer cell lines to etoposide- and cisplatin-induced cytotoxicity (Beleford et al., 2010a). These results suggest that cigarette smoke-induced down-regulation of HTRA3 could contribute to the development of chemoresistant lung cancer. |
Localisation | HtrA3 is a nuclear-encoded mitochondrial protease (Chien et al., 2009b). Localisation of HtrA3 in the mitochondrium depends on the presence of Mac25 domain and is regulated by protease function of HtrA3 (Beleford et al., 2010b). Processed forms of HtrA3 have been also found in the cytoplasm (Beleford et al., 2010b). However, HtrA3 is also classified as a secreted protein (Nie et al., 2003). |
Function | HTRA3 functions as an ATP-independent serine protease. HtrA3 has been shown to act as an inhibitor of TGF-beta signaling. HtrA3 binds to several members of the TGF-beta proteins family, including BMP4, TGF-beta1, TGF-beta2, GDF5, and suppresses signal transduction mediated by these extracellular cytokines (Tocharus et al., 2004). The proteolytic activity of HtrA3 is indispensable for this inhibitory function (Tocharus et al., 2004). HtrA3 plays a significant role during embryo implantation and formation of placenta in mammals in the early stage of pregnancy (Nie et al., 2005; Nie et al., 2006a; Nie et al., 2006b; Bowden et al., 2008). Placental HtrA3 is secreted into the maternal circulation and distinctly detectable in serum of pregnant women in the first trimester (Nie et al., 2006a). At this stage of pregnancy cellular and serum level of HtrA3 is the highest and then HtrA3 level is dramatically down-regulated by an increase of placental oxygen tension at 13-14 week of pregnancy (Li et al., 2011). HtrA3, due to its proteolytic activity, negatively regulates trophoblast invasion during placental development (Singh et al., 2010; Singh et al., 2011). HtrA3 is involved in the programmed cell death, apoptosis. It has been demonstrated that stable small hairpin RNA- and epigenetic-mediated down-regulation of HTRA3 expression attenuates cisplatin- and ethoposide-induced cytotoxicity in lung cancer cell lines while HTRA3 re-expression of proteolytic active HtrA3 promotes etopiside and cisplatine cytotoxicity (Beleford et al., 2010a, Beleford et al., 2010b). |
Homology | The HtrA3 protein is evolutionarily conserved among mammalian species. At the amino acid level homology between human HtrA3 and its orthologs from rat and mouse reaches 92,3 and 92,7 %, respectively. At least three paralogs of human HtrA3 have been identified: HtrA1 (L56, ORF480, PRSS11, ARMD7), HtrA2 (Omi) and HtrA4. HtrA3 shares the 76, 74 and 72 % homology with HtrA1, HtrA2 and HtrA4, respectively. The identity between HtrA3 and its paralogs reaches 59, 52 and 53 %, respectively. |
Review: Biochemical markers to predict preeclampsia. |
Anderson UD, Olsson MG, Kristensen KH, Akerstrom B, Hansson SR. |
Placenta. 2012 Feb;33 Suppl:S42-7. Epub 2011 Dec 23. (REVIEW) |
PMID 22197626 |
|
High temperature requirement A3 (HtrA3) promotes etoposide- and cisplatin-induced cytotoxicity in lung cancer cell lines. |
Beleford D, Rattan R, Chien J, Shridhar V. |
J Biol Chem. 2010b Apr 16;285(16):12011-27. Epub 2010 Feb 12. |
PMID 20154083 |
|
Serine proteases HTRA1 and HTRA3 are down-regulated with increasing grades of human endometrial cancer. |
Bowden MA, Di Nezza-Cossens LA, Jobling T, Salamonsen LA, Nie G. |
Gynecol Oncol. 2006 Oct;103(1):253-60. Epub 2006 May 2. |
PMID 16650464 |
|
HTRA3 expression in non-pregnant rhesus monkey ovary and endometrium, and at the maternal-fetal interface during early pregnancy. |
Bowden MA, Li Y, Liu YX, Findlay JK, Salamonsen LA, Nie G. |
Reprod Biol Endocrinol. 2008 Jun 18;6:22. |
PMID 18559118 |
|
HtrA serine proteases as potential therapeutic targets in cancer. |
Chien J, Campioni M, Shridhar V, Baldi A. |
Curr Cancer Drug Targets. 2009a Jun;9(4):451-68. |
PMID 19519315 |
|
Serine protease HtrA1 associates with microtubules and inhibits cell migration. |
Chien J, Ota T, Aletti G, Shridhar R, Boccellino M, Quagliuolo L, Baldi A, Shridhar V. |
Mol Cell Biol. 2009b Aug;29(15):4177-87. Epub 2009 May 26. |
PMID 19470753 |
|
HTRA proteases: regulated proteolysis in protein quality control. |
Clausen T, Kaiser M, Huber R, Ehrmann M. |
Nat Rev Mol Cell Biol. 2011 Mar;12(3):152-62. Epub 2011 Feb 16. (REVIEW) |
PMID 21326199 |
|
Mycoplasma synoviae induces upregulation of apoptotic genes, secretion of nitric oxide and appearance of an apoptotic phenotype in infected chicken chondrocytes. |
Dusanic D, Bencina D, Oven I, Cizelj I, Bencina M, Narat M. |
Vet Res. 2012 Jan 26;43(1):7. |
PMID 22280251 |
|
Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma. |
Hao Y, Triadafilopoulos G, Sahbaie P, Young HS, Omary MB, Lowe AW. |
Gastroenterology. 2006 Sep;131(3):925-33. |
PMID 16952561 |
|
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. |
Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, van Heek NT, Rosty C, Walter K, Sato N, Parker A, Ashfaq R, Jaffee E, Ryu B, Jones J, Eshleman JR, Yeo CJ, Cameron JL, Kern SE, Hruban RH, Brown PO, Goggins M. |
Am J Pathol. 2003 Apr;162(4):1151-62. |
PMID 12651607 |
|
Variability of origin for the neocentromeric sequences in analphoid supernumerary marker chromosomes of well-differentiated liposarcomas. |
Italiano A, Maire G, Sirvent N, Nuin PA, Keslair F, Foa C, Louis C, Aurias A, Pedeutour F. |
Cancer Lett. 2009 Jan 18;273(2):323-30. Epub 2008 Sep 26. |
PMID 18823700 |
|
Wolf-Hirschhorn syndrome due to pure and translocation forms of monosomy 4p16.1 → pter. |
Iwanowski PS, Panasiuk B, Van Buggenhout G, Murdolo M, Mys'liwiec M, Maas NM, Lattante S, Korniszewski L, Posmyk R, Pilch J, Zajaczek S, Fryns JP, Zollino M, Midro AT. |
Am J Med Genet A. 2011 Aug;155A(8):1833-47. doi: 10.1002/ajmg.a.34005. Epub 2011 Jul 8. |
PMID 21744486 |
|
Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. |
Korkola JE, Houldsworth J, Chadalavada RS, Olshen AB, Dobrzynski D, Reuter VE, Bosl GJ, Chaganti RS. |
Cancer Res. 2006 Jan 15;66(2):820-7. |
PMID 16424014 |
|
Placental HtrA3 is regulated by oxygen tension and serum levels are altered during early pregnancy in women destined to develop preeclampsia. |
Li Y, Puryer M, Lin E, Hale K, Salamonsen LA, Manuelpillai U, Tong S, Chan W, Wallace EM, Nie G. |
J Clin Endocrinol Metab. 2011 Feb;96(2):403-11. Epub 2010 Nov 3. |
PMID 21047919 |
|
Dynamic proteome in enigmatic preeclampsia: an account of molecular mechanisms and biomarker discovery. |
Mary S, Patil GV, Kulkarni AV, Kulkarni MJ, Joshi SR, Mehendale SS, Giri AP. |
Proteomics Clin Appl. 2012 Jan;6(1-2):79-90. doi: 10.1002/prca.201100089. (REVIEW) |
PMID 22447695 |
|
Expression of human HtrA1, HtrA2, HtrA3 and TGF-beta1 genes in primary endometrial cancer. |
Narkiewicz J, Lapinska-Szumczyk S, Zurawa-Janicka D, Skorko-Glonek J, Emerich J, Lipinska B. |
Oncol Rep. 2009 Jun;21(6):1529-37. |
PMID 19424634 |
|
Identification of novel endometrial targets for contraception. |
Nie G, Findlay JK, Salamonsen LA. |
Contraception. 2005 Apr;71(4):272-81. (REVIEW) |
PMID 15792646 |
|
HtrA3, a serine protease possessing an IGF-binding domain, is selectively expressed at the maternal-fetal interface during placentation in the mouse. |
Nie G, Li Y, He H, Findlay JK, Salamonsen LA. |
Placenta. 2006b Apr-May;27(4-5):491-501. Epub 2005 Jun 13. |
PMID 15951015 |
|
Identification and cloning of two isoforms of human high-temperature requirement factor A3 (HtrA3), characterization of its genomic structure and comparison of its tissue distribution with HtrA1 and HtrA2. |
Nie GY, Hampton A, Li Y, Findlay JK, Salamonsen LA. |
Biochem J. 2003 Apr 1;371(Pt 1):39-48. |
PMID 12513693 |
|
Discovery of DNA methylation markers in cervical cancer using relaxation ranking. |
Ongenaert M, Wisman GB, Volders HH, Koning AJ, Zee AG, van Criekinge W, Schuuring E. |
BMC Med Genomics. 2008 Nov 24;1:57. |
PMID 19025626 |
|
Structural and functional analysis of the PDZ domains of human HtrA1 and HtrA3. |
Runyon ST, Zhang Y, Appleton BA, Sazinsky SL, Wu P, Pan B, Wiesmann C, Skelton NJ, Sidhu SS. |
Protein Sci. 2007 Nov;16(11):2454-71. |
PMID 17962403 |
|
Decidual HtrA3 negatively regulates trophoblast invasion during human placentation. |
Singh H, Endo Y, Nie G. |
Hum Reprod. 2011 Apr;26(4):748-57. Epub 2011 Feb 14. |
PMID 21321049 |
|
Application of the wheat-germ cell-free translation system to produce high temperature requirement A3 (HtrA3) proteases. |
Singh H, Makino S, Endo Y, Li Y, Stephens AN, Nie G. |
Biotechniques. 2012 Jan;52(1):23-8. |
PMID 22229724 |
|
HtrA3 is regulated by 15-deoxy-Delta12,14-prostaglandin J2 independently of PPARgamma in clear cell renal cell carcinomas. |
Theoleyre S, Mottier S, Masson D, Denis MG. |
Biochem Biophys Res Commun. 2010 Apr 9;394(3):453-8. Epub 2009 Nov 29. |
PMID 19951697 |
|
Developmentally regulated expression of mouse HtrA3 and its role as an inhibitor of TGF-beta signaling. |
Tocharus J, Tsuchiya A, Kajikawa M, Ueta Y, Oka C, Kawaichi M. |
Dev Growth Differ. 2004 Jun;46(3):257-74. |
PMID 15206957 |
|
HtrA proteins as targets in therapy of cancer and other diseases. |
Zurawa-Janicka D, Skorko-Glonek J, Lipinska B. |
Expert Opin Ther Targets. 2010 Jul;14(7):665-79. (REVIEW) |
PMID 20469960 |
|